Spironolactone in Girls Under 12: What Parents Need to Know About Off-Label Use

Why Spironolactone Comes Up in Girls Under 12

Most women who have heard of spironolactone know it as a treatment for adult hormonal acne or PCOS. In girls under 12, the conversation is different and narrower. Spironolactone is an aldosterone antagonist and potassium-sparing diuretic that also carries significant antiandrogen activity, and it is that second mechanism that occasionally makes it relevant in young girls who present with signs of excess androgen production before or around the start of puberty.

Conditions like premature adrenarche, early-onset congenital adrenal hyperplasia (CAH), or rare androgen-secreting tumors can cause acne, body odor, pubic hair, or accelerated bone age in girls as young as six or seven. In most of these cases, treating the underlying condition is the first goal. Spironolactone is occasionally considered as an adjunct when androgen excess is causing measurable physical harm and other options have not worked.

This is off-label territory. The FDA label for spironolactone does not mention acne or hyperandrogenism in pediatric patients of any age. The labeled pediatric indications are limited to hypertension and edema.

What "Off-Label" Actually Means Here

Off-label prescribing is legal and common in pediatrics. The American Academy of Pediatrics has noted that roughly 75% of drugs used in children are used off-label at some point, because pediatric trial data lags far behind adult data. Spironolactone in girls under 12 for androgen-related conditions sits in this evidence gap.

Off-label does not mean experimental in a vacuum. It means the prescriber is applying professional judgment to a clinical situation where the formal approval pathway has not been completed, often because trials in young children are ethically complex and commercially unattractive to sponsors.

The Conditions Most Likely to Prompt This Conversation

In girls under 12, the three scenarios that most commonly lead a clinician toward considering spironolactone are:

• Premature adrenarche with documented hyperandrogenemia causing significant acne or other androgenic skin changes
• Classic or non-classic congenital adrenal hyperplasia where standard glucocorticoid therapy alone is insufficient to control androgen excess
• Rare cases of functional ovarian or adrenal hyperandrogenism diagnosed before the typical adolescent window

Each of these is a specialist diagnosis. A general pediatrician is unlikely to initiate spironolactone in a child under 12 for any of these reasons without a referral.

How Spironolactone Works, and Why That Matters in Young Girls

Spironolactone competitively inhibits aldosterone at mineralocorticoid receptors in the distal nephron, which is its primary diuretic mechanism. It also competes with dihydrotestosterone and testosterone at the androgen receptor, reducing androgenic signaling in skin, hair follicles, and sebaceous glands. This dual action is what makes it useful in androgen-driven acne and hirsutism in adult women.

In a pre-pubertal girl, that antiandrogen effect carries a different set of implications.

The Hormonal Physiology of Girls Under 12

Before puberty, girls have very low circulating androgens. Adrenarche, the maturation of the adrenal zona reticularis, normally begins around ages 6 to 8 and produces a gradual rise in dehydroepiandrosterone sulfate (DHEAS). This is separate from gonadal puberty and from the hypothalamic-pituitary-gonadal axis.

When a girl under 12 has pathologically elevated androgens, the source is almost always adrenal, not ovarian. Blocking those androgens at the receptor level with spironolactone does not treat the cause; it manages downstream effects. The risk is that suppressing androgen signaling in a child who is in a sensitive window of hormonal development could theoretically affect bone density accrual, secondary sexual development timing, and adrenal axis feedback, though direct human data on this in girls under 12 is almost entirely absent from the published literature.

Electrolyte Risks Are Age-Specific

Spironolactone blocks aldosterone, which raises serum potassium. In adults taking typical doses of 25 to 200 mg/day, hyperkalemia occurs in roughly 2 to 3% of otherwise healthy patients, but the rate rises sharply with renal impairment or co-administration of ACE inhibitors or NSAIDs. In children, renal tubular function differs from adults, and pediatric dosing guidelines for the labeled indications use weight-based calculations (1 to 3.3 mg/kg/day) precisely because fixed adult doses are not appropriate.

A young girl receiving spironolactone for any reason needs baseline and periodic electrolyte monitoring. This is not optional.

The Evidence Base: What Trials and Data Actually Exist

The honest answer is that the evidence base for spironolactone in girls under 12 for acne or hyperandrogenism is thin. Very thin.

No randomized controlled trial has been conducted specifically in girls under 12 using spironolactone for androgen-related skin conditions. The data that exists comes from three sources, and each has meaningful limitations:

Case Series in Pediatric Hyperandrogenism

Small case series have reported spironolactone use in children with CAH or premature adrenarche, usually in the context of controlling androgen excess when glucocorticoid doses were being optimized. A frequently cited case series published in the context of pediatric adrenal disorders documented androgen suppression with spironolactone doses of approximately 1 to 2 mg/kg/day in children, with generally acceptable short-term tolerability. These reports do not provide long-term follow-up data on puberty, bone density, or reproductive outcomes.

Adolescent Acne Data (Ages 12 to 17)

The better-studied population is adolescent girls aged 12 and older. A retrospective cohort published in the Journal of the American Academy of Dermatology found spironolactone effective for acne in adolescent females with mean age around 15 to 16 years, with a favorable side-effect profile. This data is sometimes extrapolated downward to younger girls, but that extrapolation is not validated.

The SPPARO Trial in Adults

The SPPARO trial published in the BMJ in 2021 was the first large randomized controlled trial of spironolactone for acne, enrolling adult women aged 18 to 45. It confirmed efficacy and acceptable tolerability in this group. It tells us nothing directly about girls under 12.

As WomanRx reviewer Elena Vasquez, MD, puts it: "When a family asks me whether spironolactone is safe for their eight-year-old daughter with severe acne from premature adrenarche, I have to be honest that we are working from adult data and small pediatric case reports, not from trials designed for her age group. That does not mean we never use it. It means we use it carefully, with specialist oversight, and we monitor closely."

This honesty matters. Families deserve to know when evidence is extrapolated rather than direct.

Life-Stage Framing: How This Differs From Adolescent and Adult Use

Spironolactone use exists on a spectrum across female life stages, and the under-12 scenario is its most evidence-poor point.

| Life Stage | Common Indication | Evidence Quality | Key Concerns | |---|---|---|---| | Girls <12 | Hyperandrogenism from CAH, premature adrenarche | Case series only | Pubertal disruption, electrolytes, no trial data | | Adolescents 12-17 | Hormonal acne, early PCOS | Retrospective cohorts | Menstrual irregularity, teratogenicity if sexually active | | Reproductive-age women | Hormonal acne, PCOS, hirsutism, hypertension | RCT data (SPPARO, others) | Teratogenicity, contraception mandatory | | Perimenopause | Acne flares, hypertension, aldosterone changes | Extrapolated from adult RCTs | Drug interactions, electrolytes with HRT | | Post-menopause | Hypertension, heart failure | Strong labeled trial data | Hyperkalemia, renal function |

Girls under 12 sit at the left edge of this table, where caution is highest and individualization is everything.

Who Might Be a Candidate, and Who Is Not

This is not a drug a parent should request for a child without specialist input. The situations where a pediatric endocrinologist might genuinely consider spironolactone in a girl under 12 are narrow.

Possible Candidates

• A girl aged 8 to 11 with confirmed hyperandrogenemia (elevated DHEAS, androstenedione, or testosterone on age-appropriate reference ranges) who has developed moderate-to-severe inflammatory acne or significant hirsutism that is affecting her quality of life
• A girl with non-classic CAH where glucocorticoid therapy alone has been insufficient to control androgen-driven symptoms
• A girl with a confirmed androgen-excess disorder where the family and specialist have had a detailed shared decision-making conversation about risks, alternatives, and monitoring

Not Appropriate For

• Girls under 12 with mild or moderate acne that has not been trialed on topical treatments such as benzoyl peroxide, topical retinoids, or topical antibiotics
• Girls with acne that lacks a hormonal or androgen-excess etiology on workup
• Girls with any significant renal impairment, given the electrolyte risks
• Any situation where the prescribing clinician is not a pediatric endocrinologist or does not have specialist consultation

Dosing Considerations for This Age Group

Because spironolactone is not approved for androgenic conditions in girls under 12, there is no FDA-endorsed dosing regimen for this use. Prescribers who use it in this context typically reference the labeled pediatric hypertension dose as a starting framework: 1 to 3.3 mg/kg/day orally, in one or two divided doses.

For antiandrogen purposes in adolescents and adults, doses of 50 to 200 mg/day are typical. In a younger, lighter child, weight-based dosing usually produces substantially lower absolute doses, which may reduce side-effect risk but also means the antiandrogen effect may be weaker.

Spironolactone is available as a tablet (25 mg, 50 mg, 100 mg) and as an oral suspension (25 mg/5 mL), which matters for younger children who cannot swallow tablets reliably. The suspension formulation allows for more precise weight-based dosing.

Monitoring should include:

• Baseline serum potassium and renal function before starting
• Repeat electrolytes at 2 to 4 weeks after initiation and after any dose change
• Blood pressure at each visit, as the drug can cause meaningful hypotension in children
• Assessment of pubertal staging at baseline and every 3 to 6 months

Pregnancy, Lactation, and Contraception: A Required Section

This section is less about the under-12 girl herself and more about what families and clinicians must understand as she ages.

Pregnancy

Spironolactone is classified as contraindicated in pregnancy based on animal data showing feminization of male fetuses at high doses. Human data is limited, but the theoretical risk of antiandrogen effects on a developing male fetus is taken seriously enough that prescribers uniformly advise against use in pregnancy. The FDA label includes a specific warning. If a girl started on spironolactone before age 12 continues it into her adolescent years and becomes sexually active, contraception becomes mandatory. This conversation must happen proactively, not reactively.

Lactation

Spironolactone and its active metabolite canrenone transfer into breast milk. For the under-12 population, this is not directly relevant. For any adolescent or adult woman taking spironolactone who is breastfeeding or planning to breastfeed, the drug is generally considered incompatible with lactation due to the antiandrogen exposure to the infant.

Contraception Requirement for Adolescents

Any post-pubertal girl or adolescent prescribed spironolactone who is or could become sexually active needs reliable contraception. This is not optional and not a minor footnote. Dermatologists and gynecologists managing older adolescents with spironolactone typically co-prescribe a combined oral contraceptive, which also addresses menstrual irregularity, a common side effect of spironolactone in adolescents.

For the under-12 age group specifically: contraception is not yet applicable, but the prescribing clinician and family must have a documented plan for what happens as the child enters puberty and the risk calculus changes.

Sex-Specific Side Effects in This Age Group

The side-effect profile of spironolactone in adult women is well characterized. Menstrual irregularity occurs in roughly 20 to 40% of adult women taking therapeutic doses. Breast tenderness is reported. Polyuria from the diuretic effect is common at higher doses.

In pre-pubertal girls, the menstrual side effects are not applicable, but several other effects deserve attention:

Gynecomastia in Boys, Breast Tissue Changes in Girls

Spironolactone-related gynecomastia is well documented in males taking the drug. In girls, the effect on breast tissue development is less well studied. Because breast development (thelarche) is an early and estrogen-driven pubertal milestone, and because spironolactone's antiandrogen effects may alter the androgen-estrogen ratio in developing girls, the theoretical concern exists that spironolactone could affect breast development timing. This has not been definitively studied in girls under 12.

Blood Pressure and Orthostatic Hypotension

Children have lower baseline blood pressure than adults. The diuretic and vasodilatory effects of spironolactone may cause symptomatic orthostatic hypotension, particularly at the start of treatment or after dose increases. Parents should be alert to dizziness, lightheadedness, or fainting in their child.

Fatigue and Urinary Frequency

The diuretic effect increases urine output. For a school-age girl, this is practically significant and should be discussed with the family so that bathroom access at school is arranged if needed.

What Parents Should Ask the Specialist

If your daughter's doctor has suggested spironolactone for any reason and she is under 12, these are direct questions worth raising:

1. What is the specific diagnosis driving this recommendation, and has the androgen excess been confirmed with blood work?
2. What alternatives have been tried or considered, and why are they not preferred?
3. What dose will she receive, and how was that dose chosen for her weight?
4. What monitoring will happen, and how often?
5. What are the signs of hyperkalemia or low blood pressure that I should watch for at home?
6. What is the plan when she enters puberty and contraception becomes relevant?
7. How long do you expect she will need this medication?

A specialist who cannot answer these questions clearly is not yet ready to prescribe.

Conditions This Drug Touches in Young Girls

Spironolactone in girls under 12 intersects with several conditions that families may encounter in specialist care:

• Premature adrenarche: Early activation of adrenal androgen production, usually benign, but sometimes associated with elevated DHEAS and androgenic skin changes.
• Congenital adrenal hyperplasia (CAH): A group of autosomal recessive disorders affecting cortisol synthesis; the most common form causes androgen excess from birth. Spironolactone may be used adjunctively.
• Functional hyperandrogenism: Excess androgen production without a discrete tumor or clear enzyme defect; more common in adolescents but can present earlier.
• Hormonal acne in early puberty: When acne develops in a girl aged 8 to 11 alongside other signs of androgen excess, a hormonal workup is warranted before any systemic treatment, including spironolactone, is considered.

These conditions require a pediatric endocrinologist as the primary specialist. Dermatologists managing acne in this age group should refer for hormonal evaluation before considering systemic antiandrogens.

The Evidence Gap: Honesty About What We Do Not Know

Women have been historically under-represented in clinical trials. Girls under 12 are even more so. No large randomized trial of spironolactone for androgenic conditions has enrolled girls in this age group, and current trial registries do not show any planned studies to fill this gap.

A 2021 systematic review of antiandrogen treatments in pediatric populations concluded that evidence for spironolactone in pre-pubertal children remains "insufficient to support routine use" outside of specialist-managed cases with clear androgenic excess.

What this means practically: prescribers in this space are making clinical judgments based on adult pharmacology, weight-based dosing principles, and small case series. That is different from having validated pediatric trial data. Families have the right to know this distinction, and any honest clinician will acknowledge it.

The FDA's pediatric labeling for spironolactone references hypertension data only and explicitly does not address androgenic indications in children. This silence is itself informative.

Practical Next Steps for Families

If your daughter is under 12 and a clinician has raised spironolactone as a possibility, the path forward looks like this:

1. Confirm the diagnosis with a pediatric endocrinologist. A referral from your pediatrician is the right starting point.
2. Get a full hormonal panel appropriate for her age: DHEAS, androstenedione, total and free testosterone, 17-hydroxyprogesterone (to screen for CAH), and a bone age X-ray if there is concern about accelerated skeletal maturation.
3. Trial topical treatments first for acne, unless the acne is clearly driven by documented hormonal excess.
4. If spironolactone is recommended, ask for a documented treatment plan with dose, monitoring schedule, and stop criteria.
5. Ask specifically what happens to the prescription when she starts puberty, becomes sexually active, or wishes to become pregnant in the future.

The drug can be used thoughtfully in very specific clinical scenarios. It is not a casual choice for a young girl, and no responsible clinician will present it as one. The Endocrine Society's clinical practice guideline on hyperandrogenism in adolescents recommends detailed diagnostic workup and specialist management before any systemic antiandrogen therapy, a principle that applies with even greater force in girls under 12.